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The majority of colorectal carcinomas are resistant to cur-
rently available cytotoxic drugs. The most effective single
agent is 5-fluorouracil, with a 20% response rate; and
randomised trials have not yet shown any benefit for
combination chemotherapy (Buroker et al., 1985). The major
metabolite of 5-fluorouracil is a potent inhibitor of thymidy-
late synthetase, though whether this is the principal mode of
cytotoxicity remains to be established (Benz & Cadman,
1981).
The antifol CB3717 (N'O propargyl-5, 8-dideazafolic acid)
was developed as a pure thymidylate synthetase inhibitor,
and found to have impressive activity in the Institute of
Cancer Research L1210 model (Jones et al., 1981). During
phase I evaluation renal toxicity was dose limiting, but most
patients also experienced transient malaise and disturbance
of liver function (Calvert et al., 1986). However, two of four
patients with colon cancers showed a minor tumour
response; therefore, this phase II study was initiated to
determine the activity of CB3717 in colorectal carcinoma.
Twenty-six consecutive patients with advanced and
measurable tumours were entered. The principal exclusion
criteria were impaired renal function (EDTA or creatinine
clearance <30mlmin-1), hyperbilirubinaemia (serum biliru-
bin > 17mmol - 1) or an ECOG performance status exceed-
ing 2. Patient characteristics are shown in Table I.
The initial dose of CB3717 was 400mgm-2 for patients
with normal renal function; those with a glomerular filt-
ration rate 30-60mlmin-1 received 300mgm2 and a single
patient with previous renal failure started treatment at
200mgm-2. The drug was infused in 250ml 1.26% sodium
bicarbonate over one hour. Blood counts, renal and hepatic
function were monitored weekly. Patients were retreated on
day 21 if there was no myelotoxicity (WBC >2.5 x 1091-;
platelets >75 x 1091-1) and CB3717 induced elevation of
aspartate transaminase (AST) or alkaline phosphatase (AP)
was resolving. If retreatment was delayed by prolonged
elevation of AST or AP, subsequent doses were reduced to
300mgm2.
Response was evaluated by standard UICC criteria after
three courses of treatment, unless there was evidence of
progressive disease prior to this. Continuing deterioration of
liver function tests between days 28 and 35 was considered
to reflect progressive disease.
Seventy-five cycles of CB3717 were administered; 58
(77%) doses were given at 400 mgm2, 15 (20%) at
300 mgm-2 and 1 each at 200 and 250mgm-2. The indica-
tions for dose reduction were impaired renal function
(n= 12) including the single patient who escalated from
200mgm 2 without problems despite prior acute renal
failure and delayed recovery from drug induced elevation of
AST or AP (n=5). The median number of treatment cycles
per patient was 3 (range 1-6).
The major toxicity (Table II) was transient malaise occur-
Correspondence: M.J. Harding.
Received 10 March 1988.
ring 3-10 days post treatment. Neither incidence, duration
nor severity of this complication was directly related to the
peak AST level. Two patients discontinued treatment after 1
and 2 doses of CB3717 as a result of severe malaise with
AST elevations of Grade 2 and 3 respectively; both had liver
metastases. In contrast 6 cycles without hepatic toxicity
biochemically were associated with significant malaise. Three
Table I Patient characteristics (n=26; 14 male, 12 female. Median
age: 58 years (range 32-72))
ECOG performance status:
0 n= 5
1 n=18
2 n= 3
Sites of metastatic disease:
liver n=11
liver and lung n= 6
bone n= 2
local recurrence+nodal disease n= 7
Prior therapy:
none
chemotherapy methotrexate+5-fluorouracil
5-fluorouracil alone
irradiation
n=13
n= 8
n= 4
n= 1
Previous response:
not evaluable, adjuvant n= 1
progressive disease n= 11
Table II Toxicity of CB3717
Evaluable
courses
n= 75
Malaise
Nausea
Vomiting
Rash
Conjunctivitis
Neuropathy
Nephropathy Grade 2
Elevation AST
In absence of liver 20:
Grade 0
1
2
3
4
In presence of liver 20:
Grade 0
1
2
3
4
33
10
9
5
8
1
1
n=31
12
2
16
1
0
n=44
3
14
16
8
3
Patients
n=26
17
8
6
5
4
1
n=9
3
5
1
0
n=17
3
5
5
3
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patients received steroids for CB3717 toxicity (30mg predni-
solone day-l for 7 days) and this appeared to reduce the
maximal AST level and ameliorate malaise. CB3717 caused
gastrointestinal disturbance in half the patients treated, but
this was neither severe nor prolonged. Myelosuppression was
insignificant; WHO Grade 1 leucopenia on one occasion
only.
Two patients are inevaluable for response: one was with-
drawn from study with unacceptable toxicity after one
course, the other developed gastrointestinal obstruction and
died at 16 days. No responses were documented among the
remaining 24 patients though 7 had disease stabilisation for
3-10 months. Median survival was 4 months (range 16 days-
32 months).
Our data suggest that CB3717 in this dose schedule is
inactive in colorectal carcinoma. Prior therapy with the
standard antifol methotrexate and/or 5-fluorouracil, both of
which inhibit thymidylate synthetase might have prejudiced
the outcome in 12 patients, but no responses occurred in the
other 12 evaluable non-treated patients. Remissions have
been seen in ovarian and breast cancer at dose levels
exceeding 200mgm-2 (Calvert et al., 1986), thus subthera-
peutic dosing is unlikely to account for the lack of activity in
colorectal cancer.
Toxicity was as expected from the phase I data, compris-
ing transient malaise and transaminase elevation. As in other
studies a clear correlation between the two has not been
established, although it seems likely that the symptoms do
relate to hepatic toxicity. In contrast to others (Calvert et al.,
1986) we did not observe the development of tolerance to the
effect of CB3717 on AST levels with repeated doses. Predni-
solone given empirically to patients with previous significant
malaise appeared to ameliorate both adverse effects of
CB3717.
In conclusion these data indicate that compounds deve-
loped specifically for their ability to inhibit thymidylate
synthetase are unlikely to prove to be active in human
colorectal cancer.
We are grateful to ICI for supplies of CB3717, the Cancer Research
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References
BENZ, C. & CADMAN, E. (1981). Modulation of 5-fluorouracil and
cytotoxicity by antimetabolite pretreatment in human colorectal
adenocarcinoma HCT-8. Cancer Res., 41, 994.
BUROKER, T.R., MOERTEL, C.G., FLEMIING, T.R. & 8 others (1985).
A controlled evaluation of recent approaches to biochemical
modulation or enhancement of 5-fluorouracil therapy in colorec-
tal carcinoma. J. Clin. Oncol., 3, 1624.
CALVERT, A.H., ALISON, D.L., HARLAND, S.J. & 9 others (1986). A
phase I evaluation of the quinazoline antifolate thymidylate
synthetase inhibitor, N10-Propargyl-5, 8-Dideazafolic Acid,
CB3717. J. Clin. Oncol., 4, 1245.
JONES, T.R., CALVERT, A.H., JACKMAN, A.L., BROWN, S.J., JONES,
M. & HARRAP, K.R. (1981). A potent antitumour quinazoline
inhibitor of thymidylate synthetase: Synthesis, biological proper-
ties and therapeutic results in mice. Eur. J. Cancer, 17, 11.